-
Rask Abbott posted an update 1 year, 5 months ago
To assess the ability of model-based personalised dosing tools to estimate busulfan exposure (i) in comparison to clinically used intensive sampling exposure estimation procedure, (ii) using limited sampling strategies and (iii) to predict changes in busulfan clearance during busulfan treatment.
Data on intravenous busulfan dosing for…[Read more]
-
Rask Abbott became a registered member 1 year, 5 months ago

